58.98
전일 마감가:
$59.73
열려 있는:
$59.98
하루 거래량:
1.25M
Relative Volume:
0.63
시가총액:
$12.10B
수익:
$4.08B
순이익/손실:
$32.48M
주가수익비율:
421.29
EPS:
0.14
순현금흐름:
$16.80M
1주 성능:
-5.68%
1개월 성능:
+0.20%
6개월 성능:
-29.26%
1년 성능:
+10.24%
인사이트 코퍼레이션 Stock (INCY) Company Profile
명칭
Incyte Corp
전화
(302) 498-6700
주소
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
INCY을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
INCY
Incyte Corp
|
58.98 | 12.10B | 4.08B | 32.48M | 16.80M | 0.14 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
인사이트 코퍼레이션 Stock (INCY) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-03-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
2025-03-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2024-12-17 | 개시 | UBS | Neutral |
2024-10-29 | 업그레이드 | BofA Securities | Neutral → Buy |
2024-10-01 | 개시 | Wolfe Research | Outperform |
2024-09-18 | 다운그레이드 | Truist | Buy → Hold |
2024-07-02 | 다운그레이드 | BMO Capital Markets | Market Perform → Underperform |
2024-05-23 | 개시 | Deutsche Bank | Hold |
2024-04-23 | 개시 | Cantor Fitzgerald | Neutral |
2024-02-23 | 개시 | Jefferies | Buy |
2024-02-14 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
2023-12-13 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2023-12-04 | 업그레이드 | Guggenheim | Neutral → Buy |
2023-11-21 | 다운그레이드 | Goldman | Buy → Neutral |
2023-07-25 | 개시 | Citigroup | Buy |
2023-05-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
2023-04-10 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2023-03-24 | 업그레이드 | SVB Securities | Underperform → Market Perform |
2023-01-31 | 개시 | Piper Sandler | Overweight |
2022-08-03 | 다운그레이드 | Evercore ISI | Outperform → In-line |
2022-08-03 | 다운그레이드 | Guggenheim | Buy → Neutral |
2022-07-28 | 개시 | Wells Fargo | Equal Weight |
2022-02-09 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
2022-01-18 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
2021-07-20 | 업그레이드 | The Benchmark Company | Hold → Buy |
2021-02-10 | 다운그레이드 | SVB Leerink | Mkt Perform → Underperform |
2021-01-07 | 개시 | Truist | Buy |
2021-01-04 | 업그레이드 | Guggenheim | Neutral → Buy |
2020-06-16 | 개시 | The Benchmark Company | Hold |
2020-05-06 | 다운그레이드 | JP Morgan | Overweight → Neutral |
2020-04-29 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-04-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-03-24 | 재개 | William Blair | Outperform |
2020-03-13 | 업그레이드 | BofA/Merrill | Neutral → Buy |
2020-02-04 | 재개 | BofA/Merrill | Neutral |
2020-01-03 | 재확인 | BMO Capital Markets | Market Perform |
2020-01-03 | 다운그레이드 | Mizuho | Buy → Neutral |
2020-01-02 | 다운그레이드 | Guggenheim | Buy → Neutral |
2019-10-03 | 개시 | Mizuho | Buy |
2019-09-12 | 개시 | BMO Capital Markets | Market Perform |
2019-09-05 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
2019-09-05 | 재개 | Morgan Stanley | Equal-Weight |
2019-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
2019-05-21 | 개시 | Credit Suisse | Neutral |
2019-05-03 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2019-04-11 | 개시 | Stifel | Hold |
2019-04-03 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2019-01-24 | 업그레이드 | William Blair | Mkt Perform → Outperform |
모두보기
인사이트 코퍼레이션 주식(INCY)의 최신 뉴스
New Incyte Suit Targets Broader Apotex Bid to Sell Jakafi Rival - Bloomberg Law News
Sun shines on Leqselvi at Federal Circuit - BioWorld MedTech
Merus annonce ses résultats financiers pour le premier trimestre 2025 et fait le point sur ses activités - GlobeNewswire Inc.
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 7, 2025 - BioSpace
Fed. Circ. Clears Way For Sun Pharma Alopecia Drug - Law360
US panel, finding no irreparable harm, vacates injunction against Sun Pharma - MLex
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | INCY Stock News - GuruFocus
Incyte Can’t Keep Sun’s Hair Drug Off Market, Appeals Court Says - Bloomberg Law News
Incyte Reports Strong Q1 2025 Financial Results and Pipeline Progress - MyChesCo
Chronic Hand Eczema Pipeline 2025: FDA Approvals, Therapies, - openPR.com
Novartis, Incyte Settle Drug Royalty Fight On Eve Of Trial - Law360
Incyte expects minimal tariff hit, lifts blood cancer drug's 2025 forecast - MSN
Polycythemia vera Market: Epidemiology, Therapies, - openPR.com
Alopecia Areata Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corp - Barchart.com
Incyte to Present at Upcoming Investor Conference - Yahoo Finance
Incyte (INCY) Target Price Raised Following Strong Q1 Performanc - GuruFocus
9 Analysts Have This To Say About IncyteIncyte (NASDAQ:INCY) - Benzinga
Incyte (INCY) Target Price Raised Following Strong Q1 Performance | INCY Stock News - GuruFocus
Incyte (INCY) Receives Adjusted Price Target from TD Cowen | INC - GuruFocus
BofA Boosts Incyte (INCY) Price Target Following Q1 Results | IN - GuruFocus
Incyte (INCY) Target Price Raised by Wells Fargo Despite Mixed R - GuruFocus
Steroid Refactory Acute Graft-Versus-Host Disease Market Growth Projections 2023-2032: DelveInsight Analysis | MaaT Pharma, Medac GmbH, AltruBio Inc., Incyte Corporation - Barchart.com
Incyte Corporation (NASDAQ:INCY) Q1 2025 Earnings Call Transcript - Insider Monkey
Incyte: Q1 Earnings Snapshot - CT Insider
Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Reve - GuruFocus
Incyte Corp (INCY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance
Incyte to Showcase Latest Oncology Advancements at 2025 ASCO Meeting - MSN
Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises - Investing.com
BofA raises Incyte stock price target to $89, maintains Buy rating - Investing.com
Earnings call transcript: Incyte Q1 2025 beats expectations, stock rises By Investing.com - Investing.com Canada
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales - The Globe and Mail
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs - BioSpace
Incyte Corp Raises Jakafi Sales Forecast Following Strong Performance - Finimize
Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key P - GuruFocus
Incyte Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Incyte Q1 2025 slides: 26% product revenue growth, Jakafi guidance raised - Investing.com
Incyte Corp (INCY) Q1 2025 Earnings: EPS of $0.80 Beats Estimate, Revenue Surges to $1.053 Billion - GuruFocus
Incyte Reports 2025 First Quarter Financial Results and Provides Updates on Key Clinical Programs | INCY Stock News - GuruFocus
Incyte Q1 Results Top Estimates - Nasdaq
Incyte (INCY) Surpasses Q1 Revenue Expectations, Driven by Key Products | INCY Stock News - GuruFocus
Incyte earnings beat by $0.12, revenue topped estimates - Investing.com
Incyte (NASDAQ:INCY) Delivers Strong Q1 Numbers - Barchart.com
Incyte Reports 2025 First Quarter Financial Results - TradingView
Incyte (INCY) Set to Announce Q1 Earnings, Analysts Cautious - GuruFocus
인사이트 코퍼레이션 (INCY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):